Table 3.
Applications of adjuvant treatment with interferon in IFN group
| Study | Intervention | Follow-up (months) |
|---|---|---|
| Ikeda K (2000) |
10 patients received natural IFN-β 6×106 twice a week for 36 months |
25.0 |
| Kubo S (2000) |
15 patients received 6×106 IFN-α intramuscularly every day for 2 weeks, then three times weekly for 14 weeks, and finally twice weekly for 88 weeks. |
60.0 |
| Shiratori Y (2003) |
49 patients received 6×106 IFN-α intramuscularly three times weekly for 48 weeks. |
85.2 |
| Lin SM (2004) |
20 patients received 3×106 IFN-α 2b intramuscularly three times weekly for 24 months. |
27.0 |
| Piao CY (2005) |
30 patients orally received 100 mg of lamivudine daily after HCC treatment. |
24.0 |
| Mazzaferro V (2006) |
76 patients received 3×106 IFN-α 2b three times weekly for 48 weeks. |
45.0 |
| Sun HC (2006) |
118 patients received 3×106 IFN-α intramuscularly twice a week for 2 weeks and then 5×106 three times weekly for 18 months. |
36.5 |
| Lo CM (2007) |
40 patients received 10×106/m2 IFN-α 2b subcutaneously three times weekly for 16 weeks. |
30.0 |
| Li M (2009) |
108 patients received IFN-α 2b 3×106 three times weekly by intramuscular injection one week. |
24.8 |
| Li N (2010) |
43 patients received lamivudine with or without adefovir dipivoxil. |
24.0 |
| Ishikawa (2012) | 29 patients received PEG-IFN α-2b/ribavirin after curative HCC treatment. | 36.0 |